Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis (NVS) stock slips despite better than expected Q3 results amid concerns over a cancer drug added with its $3B ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Not long after Basel, Switzerland, was selected as the next host of the annual Eurovision Song Contest, hometown pharma ...

In its latest financial report, Monte Rosa Therapeutics has announced a significant partnership with Novartis, alongside progress in its pipeline of drug candidates. The partnership involves a global ...

Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. | Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has ...